Management of Multiple Myeloma Through an Interprofessional Approach: Utilization of Treatment Combinations and Sequencing of Regimens

Released On
December 11, 2019

Expires On
December 11, 2020

Media Type

Completion Time
90 minutes

Hematology, Oncology, Primary Care

Multiple Myeloma

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by American Academy of CME, Inc.


Supported by an educational grant from Sanofi Genzyme.

Credit Available

  • Nurses — 1.5 contact hours (includes 0.75-hours of pharmacotherapeutic contact hours).
  • Pharmacists — 1.5 contact hours.

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

The target audiences for this initiative include oncology pharmacists, oncology nurses, nurse practitioners and nurse navigators actively engaged in patient care. Other members of the care team may also participate.

Program Overview

Multiple myeloma (MM) continues to be a pervasive disease that is encountered by the oncology care team. The treatment paradigm for this disease continues to evolve, with new treatment schemas and combination regimens continuing to emerge. As such, individuals with MM have more options for treatment of their disease and longevity has increased. Based on the constant evolution in the setting of MM, it’s important for the members of the care team to remain cognizant of their patient’s treatment options and indicated supportive care strategies. This requires an orchestrated back-and-forth between multiple healthcare professionals – including nurses, nurse practitioners and nurse navigators, pharmacists, and physicians – to discuss the patient’s clinical status, goals of therapy, optimal treatment approach, and ability to tolerate therapy. Additionally, the care team should consider the patient from a holistic approach, ensuring they have adequate support not only from a pharmacology perspective, but also from a financial and psychosocial context. Patients may suffer a severe psychological and monetary burden from the treatment of their disease, and so it’s important to gauge these elements to ensure individuals can continue therapy without significantly affecting their quality of life.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify new medication regimens for the treatment of multiple myeloma (MM) and their tier in therapy
  • Describe adverse events and management strategies of medications used to treat MM
  • Review the supportive care needs of MM patients based on their medication regimen and comorbidities
  • Describe strategies to reduce the risk of skeletal, thrombotic, and infectious complications in MM
  • Discuss the roles of the interprofessional cancer team in MM treatment and management


Marcus Flores, PharmD, BCPS, BCOP

Clinical Pharmacist, Oncology
Hackensack Meridian Health Cancer Care
Jersey Shore University Medical Center

Suzanne Penna, MSN, RN, OCN

Clinical Nurse Specialist
Middletown, NJ

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. American Academy of CME, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses and Nurse Practitioners Credit Designation

American Academy of CME, Inc., designates this educational activity for 1.5 ANCC contact hours (0.75 pharmacotherapeutic contact hours).

Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.5 contact hours.

Pharmacist Continuing Education

Accreditation Statement

This activity provides 1.5 ACPE contact hours (0.15 CEUs) of continuing education credit. Universal Activity Number JA4008191-0000-19-014-H01-P, Application.

Disclosures of Conflicts of Interest

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are able to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

Marcus Flores, PharmD, BCPS, BCOP

  • No relevant financial relationships with any commercial interests

Suzanne Penna, MSN, RN, OCN

  • No relevant financial relationships with any commercial interests.

Planning Committee

John JD Juchniewicz, MCIS, CHCP, Edward Moylan, RPh, Natalie Kirkwood, JD, BSN, RN Wendy Gloffke, PhD and Paul Miniter, MS - No relevant financial relationships with any commercial interests.

Disclosure of Unlabeled Use

This activity will review off-label or investigational information. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE/CPE credit for your participation, please complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately. For pharmacists, a statement of credit will be issued through CPE Monitor in 6-8 weeks. Only learners who provided valid NABP e-Profile ID numbers and month and day of birth (MMDD) will be submitted to CPE Monitor for official record of credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.


For more information about the American Academy of CME privacy policy, please access

For any questions, please contact:

©2019. This CE-certified activity is held as copyrighted © by American Academy of CME, Inc. Through this notice, the Academy grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).